February 3, 2020
Modulim’s new proprietary CPT code 0061U was highlighted by Kathleen Schaum, in Today’s Wound Clinic. The code can be used for capturing five transcutaneous hemoglobin biomarkers using SFDI, the core technology used in the Clarifi Imaging System.
The biomarkers can be used by clinicians for microvascular assessment and identifying potential compromised circulation due to peripheral arterial disease or diabetes.
Modulim delivers transformative optical solutions that help people live healthier, longer lives. Clarifi, powered by Spatial Frequency Domain Imaging (SFDI) technology, identifies compromised circulation at the point of care through non-contact rapid microvascular assessment of tissue. Clinicians and healthcare systems are empowered by SFDI images to make proactive, data-driven decisions in a multidisciplinary care setting, in order to reduce lower-limb complications caused by diabetes and peripheral arterial disease. Founded by the inventors of SFDI at the University of California Irvine, Modulim is based in Irvine, CA with a team dedicated to delivering powerful healthcare solutions that elevate and standardize health care delivery, while improving patient outcomes. Modulim is backed by Pangaea Ventures, Fresenius Medical Care Ventures, Grey Sky Venture Partners, Mitsubishi Capital, Hamamatsu Photonics, The Cove Fund at UCI Applied Innovation, and Fouse KK.
Clarifi is a registered trademark of Modulated Imaging (dba Modulim).